



**Financial Results**  
**- For the First Half of FYE March 2019 -**

November 12, 2018

**Meiji Holdings Co., Ltd.**

1. Overview for the First Half
2. Outlook for the Second Half and Full-year
3. Overview of Business Results and Future Business Strategy

- Information in this material is not intended to solicit sale or purchase of shares in Meiji Holdings.
- Business forecasts and other forward-looking statements are based on information available at the time of the release of this presentation and reasonable assumptions made by the Company. Actual results could differ materially from forecasts due to various factors.
- Although this material includes information concerning pharmaceutical products (including those currently under development), such descriptions are not intended to advertise the products or provide any medical advice.



# 1. Overview for the First Half


# H1 Summary - FYE March 2019




(JPY bn) Meiji HD (consolidated)	FYE March 2018 H1 Results	FYE March 2019 H1 Plan (as of Aug. 7)	FYE March 2019 H1 Results	YoY Change	Change vs. Plan
Net sales	611.4	607.0	611.9	+0.1% +0.4	+0.8% +4.9
Operating income	45.1	41.0	43.8	-2.9% -1.2	+6.9% +2.8
Op. income margin	7.4%	6.8%	7.2%	-0.2pt	+0.4pt
Net income attributable to shareholders of parent company	31.4	32.0	38.3	+21.9% +6.8	+19.7% +6.3
EPS (JPY)	216.33	220.69	264.23	+47.90	+43.54
Cash dividends per share (JPY)	57.5	65.0	65.0	+7.5	—
Capital expenditures	34.8	39.5	34.3	-1.4% -0.5	-13.3% -5.2

- Net sales increased thanks to increased revenues from the Pharmaceutical business and consolidation of KM Biologics in Q2, which covered decreased revenues from the Food Segment. Operating income decreased slightly YoY.
- Recorded a significant increase in net income due to gains on sales of fixed assets and negative goodwill raised from KM Biologics though incurred losses due to natural disasters

(JPY bn)	FYE March 2018 H1 Results	FYE March 2019 H1 Plan (as of Aug. 7)	FYE March 2019 H1 Results	YoY Change	Change vs. Plan
Food Segment					
Net sales	534.2	529.9	524.8	-1.8% -9.4	-1.0% -5.0
Operating income	40.9	38.9	39.0	-4.6% -1.9	+0.3% +0.1



(JPY bn)	FYE March 2018 H1 Results	FYE March 2019 H1 Plan (as of Aug. 7)	FYE March 2019 H1 Results	YoY Change	Change vs. Plan
Pharmaceutical Segment					
Net sales	77.7	77.9	87.6	+12.6% +9.8	+12.4% +9.6
Operating income	4.3	2.6	5.1	+17.5% +0.7	+96.2% +2.5





## 2. Outlook for the Second Half and Full-year


(JPY bn) Meiji HD (consolidated)	FYE March 2018 H2 Results	FYE March 2019 H2 Plan (as of Aug. 7)	FYE March 2019 H2 Plan (as of Nov. 7)	YoY Change
Net sales	629.3	653.0	653.5	+3.8% +24.1
Operating income	49.5	58.5	57.1	+15.4% +7.6
Op. income margin	7.8%	9.0%	8.8%	+1.0pt
Net income attributable to shareholders of parent company	29.8	31.0	32.6	+9.5% +2.8

- **Meiji HD (consolidated):** Revised H2 plans for net sales and income to reflect sales performance in H1 and consolidation of KM Biologics.
- **Food segment:** Revised net sales and income downward to reflect sales trends for Core products. Secure income, JPY 49.1 bn, announced in May.
- **Pharmaceutical segment:** Revised net sales and income forecasts upwards to reflect effect of consolidation of KM Biologics.

(JPY bn) Food Segment	FYE March 2018 H2 Results	FYE March 2019 H2 Plan (as of Aug. 7)	FYE March 2019 H2 Plan (as of Nov. 7)	YoY Change
Net sales	539.3	560.0	542.2	+0.5% +2.9
Operating income	43.2	51.1	49.1	+13.5% +5.8


## YoY Change in Operating Income

(JPY bn)



\* COGS: Costs of goods sold

(JPY bn) Pharmaceutical Segment	FYE March 2018 H2 Results	FYE March 2019 H2 Plan (as of Aug. 7)	FYE March 2019 H2 Plan (as of Nov. 7)	YoY Change
Net sales	90.6	93.7	112.3	+23.9% +21.7
Operating income	6.6	7.3	8.3	+25.7% +1.7



# Full-year Outlook - FYE March 2019





(JPY bn) Meiji HD (consolidated)	FYE March 2018 Results	FYE March 2019 Plan (as of Aug. 7)	FYE March 2019 Plan (as of Nov. 7)	YoY Change
Net sales	1,240.8	1,260.0	1,265.5	+2.0% +24.6
Operating income	94.6	99.5	101.0	+6.7% +6.3
Op. income margin	7.6%	7.9%	8.0%	+0.4pt
Net income attributable to shareholders of parent company	61.2	63.0	71.0	+15.9% +9.7
EPS (JPY)	422.15	434.48	489.61	+67.46
Cash dividends per share (JPY)	130	130	130	—
Dividend ratio	30.8%	30.0%	26.6%	-4.2pt
ROE	13.1%	12.4%	13.8%	+0.7pt
Capital expenditures	71.7	89.9	79.3	+10.6% +7.5
Net cash flow from operating activities	108.7	96.9	113.4	+4.6
Free cash flow	44.3	-7.3	3.7	-40.6

Negative goodwill  
raised from KM  
Biologics: JPY 6.5 bn

- Significant YoY increase in net income due to negative goodwill raised from KM Biologics

### 3. Overview of Business Results and Future Business Strategy



## [Market trends]

- Yogurt market overall in H1 decreased slightly YoY. Plain yogurt market recovered.
- Fierce competition  
Competitors launching many new products including fermented milk drinks

## ● Functional yogurt

- H1: Sales decreased YoY. Confirmed efficiency of newly released TV commercials
- H2: Return to growth trajectory with aggressive marketing

### R-1

Beef up promotions during the peak demand season and create an attractive display in stores

### LG21


Penetrate key message “Lactobacillus effective in the stomach”

## ● Yogurt


- H1: Sales of plain yogurt revived. Decreased net weight and set competitive price (still JPY 10/box higher than competitor).
- H2: launch new products to achieve further sales growth.



(Left: Meiji Bulgaria Yogurt LB81 Calcium and iron)  
(Right: Meiji Bulgaria Drink Yogurt Plain)



(Note) The plan for FY3/19 includes the impact from the sales price reduction due to commercial transaction system revision in April 2018.



(Note) The above year-on-year change for FY3/19 excludes the impact from the sales price reduction due to commercial transaction system revision in April 2018.

[Market trends]

- Market decreased YoY in Q1. Recovering since Q2, despite hot summer.
- Firm growth continued for dark chocolate addressing needs for the health-conscious middle-aged and elderly consumers.


- Regain sales momentum after bottoming out in Q1
  - *Chocolate Kouka* sales remained favorable and drove overall performance.
  - From Q2, sales of nuts chocolate (chocolate covered nuts) and chocolate snacks proceeded as planned. New product releases and successful campaigns support overall sales growth.
- H2: Peak demand season for chocolate. Focus on products selling well and recovery of sales for *THE Chocolate*
  - Launch new products and new flavors
  - Enhance marketing efforts to convey added value



(Left: Meiji THE Chocolate Jasmin tea)

(Right: Meiji THE Chocolate Three Assorted Flavors, limited)

Meiji's Sales  
(Sports nutrition + SAVAS Milk)  
(JPY bn)



(Note) The above sales for SAVAS Milk is included in the sales of Fresh and Fermented Dairy business.

#### [Market trends]

- Market is growing. Increasing sporting population and various sporting events seeking dynamic and active lifestyles. Market growth will continue.
- The sports protein market is seeing rapid growth due to new entrants and cheap overseas products. Ecommerce is growing.
- Retailers are developing their private label brands and thus expanding shelf space.

### ● H1: Sales for SAVAS and VAAM increased

- SAVAS, mainstay whey protein products, grew significantly and newly launched SAVAS Protein Jelly also favorable. However, sales were below plans.
- Must address issues to compete with growing ecommerce

### ● H2: Enhance sales promotions optimal to each sales channel to accelerate growth


- Expand shelf space with company-wide initiatives and build strategic partnerships with retailers
- Enhance digital marketing. Attract customers by promoting our unique added value, not price



(Left: SAVAS Milk Protein Drink)  
(Right: SAVAS Protein Jelly)


Meiji's Sales  
(JPY bn)

Cheese



- H1: Strong demand drove revenue growth. Revised pricing and product net weight in June and August
- H2: Maintain growth pace. Started new camembert cheese production line to expand production capacity


Frozen dessert



- H1: Recorded net gains. *Esse!* Sweet's launched in H2 of last year. Increased media exposure and hot weather also drove revenues.
- H2: Introduce new flavors and grow *Esse!* brand


(Note) We revised the commercial transaction system for frozen dessert in April 2017.

Foods for professional use



- H1: Expanded cream sales contributed to increased revenues though reduced the number of products
- H2: Secure stable growth. Need to evaluate supply and demand for raw milk and dairy products



Consolidated Sales Breakdown by Area  
(Based on plan for FY3/19, JPY)



## China

- Confectionery
  - Continuing stable growth in mainstay *Meltykiss* and nuts chocolate (chocolate coated nuts)
- Ice cream
  - Sales exceeded previous year and plans. Launched new products successfully and expanded sales areas
- Chilled milk and yogurt
  - Milk sales favorable. Expand production capacity to accelerate H2 growth
  - H1 yogurt sales struggled due to intense competition. Revamp products and improve sales promotions to stimulate sales


Meiji's Sales



## The U.S.

- Confectionery
  - Raise price of *Animal Crackers*, local brands
  - Favorable Meiji brand chocolate snacks such as *Hello Panda*. Strengthen sales promotion for further growth.

Consolidated Sales in Japan




(Note) The above sales do not include the sales of Biologicals business.

Started to sell some vaccines manufactured by KM Biologics in September

- **Bilanoa**, Drug for anti-allergic
  - Sales exceeded previous year and plans
  - Positive feedback from patients and doctor's evaluations
  - Enhance promotion to increase share
- **SYCREST**, Antipsychotic drug
  - Steady growth. Increasing positive feedback and the number of prescriptions
  - Establish suitable sales structure in schizophrenia domain to grow further. Achieve H2 plans
- **REFLEX**, Antidepressant drug
  - H1 sales were favorable. Generic drug becomes available in December. Sales rather uncertain for H2
  - Launch generic *REFLEX* to maintain share
- **Generic drugs**
  - Continuing sales growth despite significant NHI price reductions
  - Favorable sales of injectable antibacterial drugs

\* Excluding certain products, vaccines not subject to NHI pricing revisions.



\*Out-licensed products. Please refer to our website for details of the companies and areas out-licensed to.

- Safinamide: Applied to MHLW for Parkinson's disease on October 23
- Ziprasidone: Another product of our antipsychotic drug in addition to *SYCREST*
- OP0595: AMED has adopted for CiCLE program\* on October 22  
→ Develop as a single agent for antibacterial drug. Contribute to defeat antimicrobial resistance
- ME5343: A novel agricultural insecticide, *Inscalis* (Afidopyropen), received EPA registration in the U.S. by BASF (licensee) on October 2

\* AMED: Japan Agency for Medical Research and Development  
CiCLE: Cyclic Innovation for Clinical Empowerment

# Consolidated KM Biologics in Q2, contributing to revenues and income

KM Biologics (non-consolidated) forecast for nine-month period

Net sales

JPY 30.0 bn

Operating income

JPY 3.5 bn

(Note) Eliminations recorded at time KM Biologics are consolidated.




(Headquarters / Kumamoto Production Center)

Influenza, hepatitis A, hepatitis B, Japanese encephalitis, pertussis, diphtheria, tetanus and poliomyelitis



## Breakdown



- Social responsibilities as a supplier: 20 single-supply products and capacity to manufacture pandemic influenza vaccines for 57 million people
- Recover credibility in domestic market and promote research and development

### Governance and compliance

Improve training, management, and supervisory functions based on Meiji Group governance system to ensure management transparency

- Establish internal audit system
- Improve organizational structure, reform to function internal/external monitoring system properly
- Strengthen reporting structure (reporting, information sharing, management structure)
- Build sound whistleblowing system and improve corporate culture through compliance training

### Stable supply / quality assurance

- Strengthen quality assurance system and improve management of organization
- Dispatch Meiji experts to build stringent manufacturing control, quality control, and quality assurance system
- Rebuild pharmaceutical quality system

 Launch Credibility Recovery Project (Project Owner: Mr. Nagasato, President and representative director)

Manage progress of the Project and promote appropriate information disclosure both to internal and external company



## Appendix: Financial data

# H1 Results - FYE March 2019



(JPY bn)	FYE March 2019 H1 Results	YoY Change	Main Factors for Change
Net sales	611.9	+0.1% +0.4	— (See P4-6 for details by segment)
Operating income	43.8	-2.9% -1.2	— (See P4-6 for details by segment)
Non-operating income	1.4	-23.4% -0.4	- Change in equity in income or losses of affiliates (-0.3, yoy) [H1-FY3/18] Equity in income of affiliates (0.3) [H1-FY3/19] Equity in losses of affiliates (0.0)
Non-operating expenses	1.4	+52.7% +0.5	- Change in impact from foreign exchange (-0.7, yoy) [H1-FY3/18] Foreign exchange gains (0.1) [H1-FY3/19] Foreign exchange losses (0.5)
Ordinary income	43.8	-4.9% -2.2	—
Extraordinary income	13.3	+293.3% +9.9	- Gain on bargain purchase (+6.5) - Gain on sales of fixed assets (+3.7)
Extraordinary losses	4.1	+54.3% +1.4	- Loss on disaster (+1.0) - Impairment loss (+0.8): from the former R&D centers - Loss on retirement of non-current assets (-0.9)
Income before income tax	53.1	+13.4% +6.2	—
Income taxes-total	14.4	-2.6% -0.3	—
Net income attributable to non-controlling shareholders	0.3	-44.0 % -0.2	—
Net income attributable to shareholders of parent company	38.3	+21.9% +6.8	—

# H1 Results - FYE March 2019: Analysis of Consolidated Operating Income



(JPY bn)	Consolidated Results	Food	Pharma	Other
H1 Results -- FYE March 2018	<b>45.1</b>	<b>40.9</b>	<b>4.3</b>	<b>-0.1</b>
Due to increased/decreased sales	-0.5	-2.8	+2.3	—
Decrease due to NHI drug price reduction	-6.0	—	-6.0	—
Changes in costs of goods sold	+5.3 <sup>(*1)</sup>	+1.5	+3.8	—
Changes in other SG&A expenses	+1.5 <sup>(*2)</sup>	+1.0	+0.5	—
Other (incl. change in results of subsidiaries)	-1.6	-1.6	+0.2	-0.2
H1 Results -- FYE March 2019	<b>43.8</b>	<b>39.0</b>	<b>5.1</b>	<b>-0.2</b>

(Breakdown)

\*1: **Food** Decrease in raw materials costs: +0.9, Other cost reduction: +0.5

**Pharma** Cost reductions and favorable variance from inventory reevaluation due to a production site closing

\*2: **Food** Increase in promotion expenses: -0.9, Increase in distribution expenses: -0.4, Other cost reduction: +2.3

**Pharma** Decrease in R&D expenses (Carry over to the second half): +0.7, Other cost increase: -0.2

# Financial Position as of September 2018



(JPY bn)	Results as of Sep. 2018	YoY Change	Main Factors for Change
Current assets	415.8	+8.6% +32.8	- Notes and accounts receivable (+7.5) - Goods and products (+19.0), Raw materials and supplies (+7.5): due to consolidation of KM Biologics
Fixed assets	588.0	+8.4% +45.7	- Buildings and structures (net) (+18.2), Machinery and equipment (net) (+13.0): due to consolidation of KM Biologics - Investment securities (+7.5): market value increase - Construction in progress (+6.3)
Total assets	1,003.9	+8.5% +78.6	—
Current liabilities	293.4	-0.3% -0.9	- Commercial paper (+11.0) - Short-term loans payable (-8.4)
Long-term liabilities	157.5	+16.2% +21.9	- Long-term loans payable (+15.1)
Total liabilities	451.0	+4.9% +20.9	—
Shareholders' equity	493.4	+6.0% +27.8	- Retained earnings (+27.5)
Accumulated other comprehensive income	27.0	+24.5% +5.3	- Valuation difference on available-for-sale securities (+5.7)
Minority interests	32.3	+311.8% +24.5	—
Total net assets	552.8	+11.6% +57.6	—
Interest bearing debt	136.7	+14.8% +17.6	- Long-term loans payable (+15.1)      - Commercial paper (+11.0) - Short-term loans payable (-8.4)
Equity Ratio	51.8%	-0.9pt	—

# H1 Results - FYE March 2019: Cash Flows and Shareholders' Return

(JPY bn)	FYE March 2019 H1 Results	YoY Change	Main Factors for Change
Net cash flow from operating activities	38.3	-0.3	—
Net cash flow from investing activities	-60.2	-27.5	- Payments for purchase of shares of subsidiaries resulting in change in scope of consolidation (-33.8) - Proceeds from sales of property, plant and equipment and intangible fixed assets (+5.7): a vacant lot of a former production site, an office building
Free cash flow	-21.8	-27.9	—
Cash dividends per share (JPY)	65.0	+7.5	

# Plan - FYE March 2019



(JPY bn)		First Half Results		Second Half Plan (as of Nov. 7)		Full Year Plan (as of Nov. 7)	
			YoY Change		YoY change		YoY Change
Meiji Holdings	Net sales	611.9	+0.1% +0.4	653.5	+3.8% +24.1	1,265.5	+2.0% +24.6
	Operating income	43.8	-2.9% -1.2	57.1	+15.4% +7.6	101.0	+6.7% +6.3
	Op. income margin	43.8	-4.9% -2.2	57.1	+14.8% +7.3	101.0	+5.3% +5.1
	Net income attributable to shareholders of parent company	38.3	+21.9% +6.8	32.6	+9.5% +2.8	71.0	+15.9% +9.7
Food	Net sales	524.8	-1.8% -9.4	542.2	+0.5% +2.9	1,067.1	-0.6% -6.5
	Operating income	39.0	-4.6% -1.9	49.1	+13.5% +5.8	88.1	+4.7% +3.9
Pharma	Net sales	87.6	+12.6% +9.8	112.3	+23.9% +21.7	200.0	+18.7% +31.5
	Operating income	5.1	+17.5% +0.7	8.3	+25.7% +1.7	13.5	+22.4% +2.4

# Plan by Business in Food Segment - FYE March 2019



(JPY bn)		First Half Results		Second Half Plan (as of Nov. 7)		Full Year Plan (as of Nov. 7)	
			YoY Change		YoY change		YoY Change
Fresh and Fermented Dairy	Net sales	165.5	-3.0% -5.0	166.9	-0.6% -0.9	332.4	-1.8% -6.0
	Operating income	22.4	-9.0% -2.2	26.5	-3.4% -0.9	48.9	-6.0% -3.1
Processed Food	Net sales	91.4	+2.8% +2.4	85.0	-0.3% -0.2	176.4	+1.3% +2.2
	Operating income	4.3	+9.1% +0.3	3.9	+16.7% +0.5	8.3	+12.6% +0.9
Confectionery	Net sales	50.4	-15.1% -8.9	74.1	-2.7% -2.0	124.5	-8.2% -11.0
	Operating income	6.2	-13.7% -0.9	15.3	+23.5% +2.9	21.6	+9.8% +1.9
Nutrition	Net sales	44.5	+2.4% +1.0	41.1	+1.4% +0.5	85.7	+1.9% +1.5
	Operating income	7.2	+0.3% +0.0	6.0	+17.1% +0.8	13.3	+7.4% +0.9

# Plan by Business in Food Segment - FYE March 2019



(JPY bn)		First Half		Second Half		Full Year	
		Results	YoY Change	Plan (as of Nov. 7)	YoY change	Plan (as of Nov. 7)	YoY Change
Overseas	Net sales	21.7	+5.8% +1.1	27.3	+19.2% +4.4	49.0	+12.9% +5.5
	Operating income	0.5	+48.3% +0.1	0.5	+41.4% +0.1	1.0	+44.8% +0.3
Other Domestic Subsidiaries	Net sales	151.1	-0.1% -0.1	147.7	+0.9% +1.2	298.9	+0.4% +1.1
	Operating income	2.3	-10.5% -0.2	1.8	+7.5% +0.1	4.1	-3.5% -0.1
Corporate Expenses	Net sales	—	—	—	—	—	—
	Operating income	-4.1	—	-5.1	—	-9.3	—

# Full-year Plan - FYE March 2019: Analysis of Consolidated Operating Income



(JPY bn)	Consolidated Plan	Food	Pharma	Other
Results -- FYE March 2018	<b>94.6</b>	<b>84.1</b>	<b>11.0</b>	<b>-0.5</b>
Due to increased/decreased sales	+4.9	+0.9	+4.0	—
Decrease due to NHI drug price reduction	-12.5	—	-12.5	—
Changes in costs of goods sold	+9.5	+0.5	+9.0	—
Changes in other SG&A expenses	+3.6 (*1)	+3.8	-0.2	—
Other (incl. change in results of subsidiaries)	+0.9	-1.3	+2.2	-0.0
Plan -- FYE March 2019	<b>101.0</b>	<b>88.1</b>	<b>13.5</b>	<b>-0.6</b>


(Breakdown)

\*1: **Food** Increase in promotion expenses: -0.9, Increase in distribution expenses: -1.1, Other cost reduction: +5.8


**Pharma** Decrease in R&D expenses: +0.5, Other cost increase: -0.7

(JPY bn)	FYE March 2018 Results	FYE March 2019 Plan (as of Aug. 7)	FYE March 2019 Plan (as of Nov. 7)	YoY Change
Net sales	1,073.6	1,090.0	1,067.1	-0.6% -6.5
Operating income	84.1	90.0	88.1	+4.7% +3.9

## YoY Change in Operating Income



(JPY bn)	FYE March 2018 Results	FYE March 2019 Plan (as of Aug. 7)	FYE March 2019 Plan (as of Nov. 7)	YoY Change
Net sales	168.4	171.6	200.0	+18.7% +31.5
Operating income	11.0	10.0	13.5	+22.4% +2.4




# Plan - FYE March 2019: Cash Flows and Shareholders' Return

(JPY bn)	FYE March 2019 Plan	YoY Change	Main Factors for Change
Net cash flow from operating activities	113.4	+4.6	- Mainly due to consolidation of KM Biologics
Net cash flow from investing activities	-109.7	-45.3	- Increase in CAPEX [The amounts of CAPEX for FY3/19] Food: 68.1 (+4.2, yoy) Pharma: 11.1 (+3.2, yoy) - Payments for purchase of shares of subsidiaries resulting in change in scope of consolidation: KM Biologics
Free cash flow	3.7	-40.6	—
Cash dividends per share (JPY)	130	—	(2Q) JPY 65 (Year-end) JPY 65
Payout ratio	26.6%	-4.2pt	—
ROE	13.8%	+0.7pt	—

# Key Currencies and Our Average Exchange Rates



## Key Currencies and Our Average Exchange Rates



## Foreign exchange target

For FYE March 2019





USD	Food: JPY 115 Pharma: JPY 110
EUR	Food: JPY 135 Pharma: JPY 130
RMB	Food: JPY 18 Pharma: JPY 16

For Medium-term plan


USD	Food: JPY 115 Pharma: JPY 110
EUR	Food: JPY 125 Pharma: JPY 120
RMB	Food and Pharma: JPY 16

## Appendix: Topics


# Market Trends in Imported Raw Materials Prices




# R&D Pipeline



# R&D Pipeline



\* Discovered in a research collaboration between Meiji Seika Pharma and The Kitasato Institute



**meiji**

